Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Why Now Is The Right Time For Mutual Recognition

Executive Summary

20 years later, signs that this time the US EU mutual recognition agreement won’t fizzle.

You may also be interested in...

PIC/S Interprets Checklist For Auditing Drug GMP Inspectorates

What makes a strong pharmaceutical inspectorate? It starts with some very specific legislative requirements that apply globally, inspectorate association explains.

Don’t Let Trade Issues Interfere With Drug Inspection Coordination, Experts Say

US National Academies panel diverges on how to focus pharmaceutical inspectorates’ mutual reliance arrangements on public health goals.

US/EU Agreement Will Reduce Global Import Testing Burden

US drug makers will no longer have to retest batches exported to the EU under a mutual recognition agreement provision expected to take effect by July 2019. It's a landmark development in industry's quest to eliminate import testing, which it says wastes time and resources. But many nations around the world still require import testing – our interactive map shows which rules apply where.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts